|
|
Article: AMPK Activator Licensing Deal Highlights Successful Collaboration between Boston-based Mercury Therapeutics and CreaGen Biosciences.
- Article from:
- Cancer Weekly
- Article date:
- November 10, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released (see also CreaGen Biosciences, Inc.).
For the past three years, Mercury has partnered with CreaGen for medicinal chemistry-based outsourcing of their lead generation program seeking to develop small molecule activators of AMP activated protein kinase. Novel AMPK activators hold promise for the treatment of type 2 diabetes, cardiovascular disease, and cancer.
The collaboration between Mercury and CreaGen has produced valuable intellectual property ...
Related newspaper, magazine, and journal articles:
|
|
Article: DEBIOPHARM/MERCURY SIGN LICENSE AGREEMENT FOR DEBIO 0930.
Worldwide Biotech;
September 1, 2009 ;
700+ words
... ... target unmet medical needs, and Mercury Therapeutics, Inc. (Mercury), a privately ... debiopharm.com. About Mercury Therapeutics, Inc. Located in Woburn, Massachusetts, Mercury Therapeutics is a privately held biotech ...
|
|